Back

Integrated Metabolomics and Transcriptomics Analysis Identifies Molecular Subtypes within the Early and Late Mild Cognitive Impairment Stages of Alzheimer's Disease

Yadav, S.; Zhou, S.; Karas, Z.; Zhang, Y.; Garmire, L. X.; ADNI Consortium,

2023-04-07 genetic and genomic medicine
10.1101/2023.04.06.23288268 medRxiv
Show abstract

Alzheimers disease (AD) is a heterogeneous neurodegenerative condition. This study identifies clinically relevant new molecular subtypes of the early and late mild cognitive impairment (EMCI and LMCI) stages of AD from 401 patients in the ADNI consortium. Metabolomics and peripheral blood mononuclear cell (PBMC) transcriptomics data are integrated using Similarity Network Fusion (SNF), resulting in two molecular subtypes within EMCI (EMCI-1 and EMCI-2) and LMCI (LMCI-1 and LMCI-2), respectively. Metabolomics, rather than gene expression profiling, is the major contributor to subtyping. Subtype-specific differences in metabolite levels and gene expression correlate with AD pathophysiology, supported by cognitive scores, pseudo-trajectory analysis, and longitudinal dementia diagnoses. The new molecular subtypes are further validated through the EFIGA dataset, and present a clear trend of increase in protein biomarkers including p-Tau181, p-Tau217, A{beta}40, and A{beta}42. These refined subtypes represent a step toward more personalized therapeutic strategies targeting early disease stages before AD diagnosis.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above